LONDON – Iteos Therapeutics SA is moving to plot a route forward for its lead program, EOS-200271, after Pfizer Inc. cut short a phase I study in glioblastoma and handed back rights to the indoleamine 2,3-dioxygenase (IDO-1) inhibitor.